Abbott Laboratories (ABT)

121.50
1.06 0.86
NYSE
Prev Close 122.56
Open 122.55
Day Low/High 121.28 / 122.83
52 Wk Low/High 61.61 / 115.14
Volume 4.73M
Exchange NYSE
Shares Outstanding 1771.53B
Market Cap 214.43B
P/E Ratio 60.02
Div & Yield N.A. (N.A)

Early-Morning Market Look

Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...

Wells Healthcare Conf.

Rules of the Game: Identifying Growth Stocks

Rules of the Game: Identifying Growth Stocks

The objective of investing is to offset future liabilities and manage risk.

ABT Investor Mtg.

Cramer Talks Abbott & Glaxo

Cramer Talks Abbott & Glaxo

TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.

Health Care Stocks Still Promising

Health Care Stocks Still Promising

Plenty of leadership remains in the health care sector and there's reason to see further potential.

Seven to Watch

Seven to Watch

Trading at 7x earnings, these stocks are all poised to outperform the market this year.

Barclays Healthcare Conf.

It's a Good Time to Buy All-Weather Laggards

It's a Good Time to Buy All-Weather Laggards

Don't chase recent winners, search for stocks that have good 2013 prospects.

Abbott target raised at Jefferies

Market on Close Imbalances

How much to sell? My mavens on the floor see $1.6 billion to sell market on close, so my observation earlier in the afternoon might have had some merit. In terms of sectors, the largest to buy include   health care ($ 85 ,million) and financials ($3...

Separating 'Facts' From 'Guidance'

Separating 'Facts' From 'Guidance'

Being behind the market or beating estimates isn't enough; guidance has to be good.

Chairman's Club Call Roundup

Chairman's Club Call Roundup

Markets would soar to all-time highs if our country's budget issues finally get resolved.

Chairman's Club Call Roundup

Chairman's Club Call Roundup

Markets would soar to all-time highs if our country's budget issues finally get resolved.

Blown Away by Transports, Drugs

Blown Away by Transports, Drugs

Not so much by the financials.

Updating Past Recommendations: ADM, GLW, MET, STJ, GLW

Updating Past Recommendations: ADM, GLW, MET, STJ, GLW

Recent company-related activities are worth noting and could merit action.

A Closer Look at Abbott Labs

A Closer Look at Abbott Labs

Nicole Urken, research associate of Jim Cramer, likes Abbott Labs and says it's not just an Obama trade.

Still Some Standouts

Still Some Standouts

Some sectors -- albeit, boring ones -- are acting well.

Abbott Laboratories upgraded at Wells

Watch Out for the Tightrope

Watch Out for the Tightrope

It's been a thoroughly boring, commonsense rally.

Britol-Myers Squibb Catches a Ride

Abbott gets some good news on its Hep C drug, which has buoyed Bristol-Myers. Some positive Hep C data out of Abbott Labs (ABT) (hat tip Steph Link!) is buyoing Bristol-Myers Squibb (BMY) this morning.

The 5 Dumbest Things on Wall Street: October 5

The 5 Dumbest Things on Wall Street: October 5

Here is this week's roundup of the dumbest actions on Wall Street.

The Next Big Thing in Biotech: Hepatitis Drugs

The Next Big Thing in Biotech: Hepatitis Drugs

Senior columnist Adam Feuerstein says hepatitis drugs are the next big thing to watch in biotech.

Abbott numbers raised at Jefferies

Abbott Labs, UPS Ready to Deliver

Abbott Labs, UPS Ready to Deliver

In this episode of Buy This, Sell That!, Robert Zagunis, portfolio manager for the Jensen Quality Growth fund, names his favorite stocks including Abbott Labs, UPS and Praxair.